Proteomics
- Home
- Proteomics
Predictive test for diabetic kidney disease receives new patent
12% of global health expenditure is spent on diabetes. That equates to approximately USD $673 billion. Scarily, 1 in 2 adults with diabetes is undiagnosed. Diabetic kidney disease (DKD) is directly caused by diabetes, and the damage the disease does to the kidneys. It is estimated that 1 in 3 diabetics will go on to
Read MorePublic
Study results emerge for Proteomics International Laboratories’ latest cancer diagnostic test
Your Friday crash course: Diagnostic biomarkers are in essence, used to determine whether or not a patient has a medical condition. Biomarkers can be molecular, histologic, radiographic and physiological, examples include heart rate, BMI and x-ray findings. Proteomics International Laboratories (ASX: PIQ) is taking molecular biomarkers to a whole new level, utilising proprietary biomarkers to
Read MorePublic
Proteomics International to collaborate on world first blood test for endometriosis
One in nine Australian women will suffer from endometriosis, a debilitating, chronic menstrual health disorder resulting in serious pain, fertility issues and reduced quality of life. The disease occurs when tissue similar to that within the lining of the uterus grows outside of the uterus in other areas of the body, commonly around the reproductive
Read MorePublic
Proteomics secures CE Mark certification for world’s first diabetic kidney disease diagnostic device
Australian medtech developer Proteomics International Laboratories (PILL, ASX: PIQ) has reached a landmark milestone having secured CE Mark certification for commericalisation of their in vitro diagnostic medical device in Europe, which can predict the early onset of diabetic kidney disease. The device, PromarkerD, takes a blood test which then creates a unique protein fingerprint which
Read MorePublic